The Generic Is on the Shelf, Not in the Tender

Generic apixabán reached Mexican pharmacy chains in 2026 at MXN 598 for a 60-tablet box. The innovator brand Elicuis sits on the same shelf at MXN 2,205. That is 72.9 per cent lower, it is the first price movement this molecule has recorded in Mexico, and it happened in exactly one of the two channels that buy it.

The other channel is public procurement, and it did not move. Generic manufacturers hold COFEPRIS registrations and have won their own court rulings; a further innovator amparo keeps them out of institutional purchasing anyway. The country now runs two prices for one molecule, and the cheaper of the two is available only to the buyer standing at a counter.

That split has a price on it. Institutional purchasing transacts MXN 1,589.3 million a year — 28.0 per cent of the entire Mexican apixaban market — for 94,600 patient-years at MXN 16,800 that the counter already sells at MXN 7,176. Bought at the generic rung those patient-years would cost MXN 678.8 million. The MXN 910.5 million difference is what the procurement block is worth every year, and it is not a forecast: it is the 2025 base restated at two prices that are both on the page.

The box is a month, so a shelf price is an annual price

Most molecules make you do work to turn a retail listing into a market price — a course length, a pack size, a compliance assumption. Apixabán removes that work. It is dosed at 5 mg twice daily, so a 60-tablet box is thirty days and twelve boxes are a patient-year. MXN 598 becomes MXN 7,176. The innovator box becomes MXN 26,460. No modelling step sits between the shelf and the annual figure.

That is why this market can be built from chain listings rather than from a national average price. The listings supply the price; the epidemiology supplies the volume. What the substitution itself looks like across a whole portfolio is the subject of the global generic drug market — the price step lands at the point of registration, and the volume response follows with a lag measured in quarters. In Mexico the registration has landed and the volume response is in its first year.

Two channels, two prices, one molecule

Retail is the larger channel at 141,900 patient-years, and it is also the more expensive one at MXN 28,800 a patient-year. Institutional purchasing covers 94,600 patient-years — 40.0 per cent of the total — at MXN 16,800. Blended, 236,500 patient-years at MXN 24,000 gives MXN 5,676.0 million, or USD 303.5 million at the Banco de Mexico rate of 18.7005 to the dollar published in the Diario Oficial on 23 October 2026.

Read those two prices in the order a normal generic market would produce them and they are upside down. The channel that can buy from a registered generic is paying 71 per cent more per patient-year than the channel that cannot.

That inversion is a pre-generic artefact, and it is already unwinding

Nothing about the retail price had been tested before 2026. Chain pharmacy cleared at an innovator-derived price because there was no alternative box to put beside it, while institutional tenders had been awarded below that level for years — public purchasing negotiates, the counter does not. A 1.71 times premium between the two is what that history looks like once you add it up.

By 2033 the premium is 1.10 times. The direction of that convergence matters more than its size, because it is not institutional purchasing falling to meet retail. Institutional is held at a branded price by the litigation while retail is not, so the ratio closes because the expensive channel gets cheap — retail drops toward the tender, and the tender barely moves.

The forecast runs on the observed shelf ladder rather than on a single curve. The generic rung is held flat at MXN 7,176 a patient-year for the whole eight years, which is the current chain private-label price and not an assumption about future competition. The branded rung declines from MXN 23,300 to MXN 19,700. The two are blended by a generic share that goes from 18 per cent in 2026 to 74 per cent in 2033, which is what produces MXN 20,400 falling to MXN 10,430. Almost all of the eight-year price decline is mix, not inflation or deflation.

What actually grows

Patients, steadily. The diagnosed atrial fibrillation population rises from 1.50 million to 1.65 million, anticoagulation coverage from 46 to 58 per cent, and apixabán’s share of oral anticoagulation from 30 to 38 per cent. Treatment of venous thromboembolism and post-orthopaedic prophylaxis adds 54,340 patient-years on top. The total goes from 236,500 to 418,000, an increase of 76.7 per cent, and it is the demand behind that number which the global stroke market sizes at its widest — anticoagulation is a stroke-prevention decision before it is a pharmaceutical one.

Against that, revenue falls 23.2 per cent, from MXN 5,676.0 million to MXN 4,359.7 million, or USD 303.5 million to USD 233.1 million. Volume compounds at 7.38 per cent a year and revenue compounds down at 3.24 per cent. Revenue per patient-year is the whole difference: MXN 24,000 to MXN 10,430, a fall of 56.5 per cent.

A market that treats 76.7 per cent more people and earns 23.2 per cent less is not a market in decline. It is a market being repriced, and the repricing is arithmetic rather than speculation, because the generic share and the two rungs it blends are all observable today.

Where the entrant’s margin is actually set

At MXN 7,176 a patient-year the generic rung is held flat, and that makes the next eight years a competition on cost rather than on price. Roughly half of what an entrant keeps is decided at the input contract rather than at the pharmacy, which is the field the active pharmaceutical ingredient market prices — and the one place a Mexican entrant with no brand equity can still lose the next decade.

The other half is decided by what converts a list price into a price someone else pays. Retail in Mexico is largely out-of-pocket, which is precisely why the shelf moved first: no formulary had to approve it and no tender had to be re-run. Institutional purchasing is the opposite, and the mechanics of reimbursement and formulary position that govern it are what the prescription drugs market describes at portfolio level. A market split this cleanly between a channel that has already repriced and one that has not is a market where channel access is worth more than share of voice.

The post-patent decade in cardiovascular therapy has a template, and the global statin market is eight years further along it: the price collapses, the treated population expands, and the total value stabilises at a level set by volume long after the price has finished falling. Mexico’s apixabán market is in the first year of that sequence, with one difference — the second channel is being kept out by a court rather than by a molecule.

The shelf moved and the tender did not

What happens next in this market is not really a question about apixabán. The molecule is generic, registered, on shelves and priced at a quarter of what it cost in 2025. The question is whether public procurement ever joins the retail shelf, and on the current litigation it does not inside the forecast window.

Which leaves Mexico buying the same box at two prices: the lowest one at the counter, to whoever walks in, and the innovator’s price to the institution that has already been offered the alternative. The volume grows either way. It is only the revenue that depends on which of the two the country keeps paying.

Pheonix Research publishes the full market sizing, channel split, year-by-year path and competitive position in Mexico Apixaban Market Size, Share and Forecast 2026–2033, and announces the same findings in the accompanying press release.